CureVac N.V. (CVAC) Analyse boursière

Présentation de l'entreprise

CureVac N.V. operates as a biopharmaceutical entity dedicated to developing transformative therapeutic agents based on messenger ribonucleic acid (mRNA) technology for various diseases. The company functions within the healthcare sector, specifically the biotechnology industry, positioning itself at the intersection of advanced biomanufacturing and clinical research. As of December 18, 2025, the company's total market capitalization stands at $1.05B, supported by an annual trailing twelve-month revenue of $70.74M and a workforce of 825 employees. These valuation and revenue metrics suggest the entity maintains a significant but specialized position in the mRNA landscape, reflecting its focus on high-value, early-stage candidates while managing operations on a mid-sized scale relative to large-cap pharmaceutical peers. The acquisition by BioNTech SE as of the specified date further contextualizes the company's strategic shift and market positioning within the broader biotech ecosystem.

Santé financière

The company reported trailing twelve-month revenue of $70.74M alongside a net income of $128.82M and an EBITDA of $193.69M, creating a distinct disparity between top-line sales and bottom-line profitability. This substantial gap between revenue and net income reveals a cost structure where non-operating income, likely from investments or other corporate activities, significantly augments the reported earnings beyond the core operational results. Regarding cash flow metrics, the reported free cash flow is listed as N/A, which implies that the company's liquidity analysis relies heavily on its cash balance rather than operational cash generation for this reporting period. The balance sheet shows a cash position of $416.09M against total debt of $35.07M, a configuration that indicates a highly conservative and liquid financial stance. The debt-to-equity ratio of 4.03, while mathematically high, must be interpreted in the context of the massive cash reserves, suggesting the leverage does not present immediate solvency risks. Short-term liquidity is robust, evidenced by a current ratio of 3.70, indicating the company holds ample current assets to cover its short-term liabilities with significant ease. Return on Equity and Return on Assets are both listed as N/A, preventing a direct assessment of management effectiveness through these traditional return metrics in the current reporting framework.

Évaluation de la valorisation

The valuation metrics display a notable divergence between the trailing P/E ratio of 6.96 and the forward P/E of -8.02, implying that expected earnings trajectory is currently negative or that future earnings estimates have not yet materialized to support a positive multiple. The price-to-book ratio stands at 0.83, indicating that the market values the company's equity at a discount relative to its book value, a common characteristic for biotechnology firms with significant intangible assets and high R&D costs. Alternative valuation measures such as the price-to-sales ratio of 14.83 and an EV/EBITDA of 2.39 suggest that investors are pricing the company based on revenue growth potential and EBITDA efficiency rather than current earnings power. The stock has traded between a 52-week high of $5.72 and a 52-week low of $2.48, meaning the current price sits at a level that reflects the volatility inherent in the mRNA sector. With a beta of 1.84, the stock exhibits high price volatility relative to the broader market, moving with significantly greater intensity than the benchmark index.

Growth & Income

The company experienced a year-over-year revenue growth of -89.0% and an earnings growth of 24.0%, indicating that earnings are growing faster than revenue, which is typically driven by non-operating income or cost reductions rather than top-line expansion. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company is not a dividend payer and instead reinvests any generated earnings back into research, development, or balance sheet strengthening. This non-dividend status aligns with the typical lifecycle of a biotechnology company that prioritizes capital allocation toward clinical trials and asset acquisition over shareholder distributions. The overall growth and income profile is characterized by a contraction in top-line sales offset by a rebound in profitability, while the absence of dividends directs all financial resources toward sustaining the company's transformative mRNA pipeline.